Outcome of patients with multiple myeloma and hypotension during high‐dose chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|6|E125-E127

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.6, 2015-06, pp. : E125-E127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-Dose Chemotherapy with Hematopoietic Stem Cell Transplantation for Patients with Advanced Multiple Myeloma

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-07 ,pp. : 272-274

Karger

Access to resources Recommend Favorite

High-Dose Idarubicin, Busulphan and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma Responsive to DAV Chemotherapy: Comparison with a Historical Control

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 9-14

Karger

Access to resources Recommend Favorite

Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E73-E74

John Wiley & Sons Inc

Access to resources Recommend Favorite

Monitoring Hyperhydration during High-Dose Chemotherapy: Body Weight or Fluid Balance?

By  

Acta Haematologica, Vol. 109, Iss. 4, 2003-07 ,pp. : 163-168

Karger

Access to resources Recommend Favorite

Intermediate-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor Is a Valid Alternative to High-Dose Cyclophosphamide for Mobilizing Peripheral Blood CD34+ Cells in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 109, Iss. 4, 2003-07 ,pp. : 184-188

Karger

Access to resources Recommend Favorite